FAM89B Human shRNA Plasmid Kit (Locus ID 23625)
CAT#: TL319734
FAM89B - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector, 5µg of each construct provided
Need custom shRNA service?
Get a free quote
CNY 7,740.00
货期*
2周
规格
Product images
![](https://cdn.origene.com/img/defaults-img.jpg)
经常一起买 (4)
Lateral flow testing sticks used for the semi-quantitative detection of the lentiviral p24 protein, 20 tests
CNY 4,070.00
Specifications
Product Data | |
Product Name | FAM89B Human shRNA Plasmid Kit (Locus ID 23625) |
Locus ID | 23625 |
UniProt ID | Q8N5H3 |
Synonyms | LRAP25; MTVR; MTVR1 |
Vector | pGFP-C-shLenti |
Format | Lentiviral plasmids |
Kit Components | FAM89B - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 23625). 5µg purified plasmid DNA per construct29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free. |
RefSeq | BC023991, NM_001098784, NM_001098785, NM_152832, NM_152832.1, NM_152832.2, NM_001098784.1, NM_001098785.1, BC023991.2, BC032373, BC032373.1, NM_001098784.2, NM_001098785.2, NM_152832.3 |
Summary | Negatively regulates TGF-beta-induced signaling; in cooperation with SKI prevents the translocation of SMAD2 from the nucleus to the cytoplasm in response to TGF-beta. Acts as an adapter that mediates the specific recognition of LIMK1 by CDC42BPA and CDC42BPB in the lamellipodia. LRAP25-mediated CDC42BPA/CDC42BPB targeting to LIMK1 and the lamellipodium results in LIMK1 activation and the subsequent phosphorylation of CFL1 which is important for lamellipodial F-actin regulation.[UniProtKB/Swiss-Prot Function] |
shRNA Design | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service. |
Performance Guaranteed | OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred). |
Documents
Product Manuals |
FAQs |
SDS |
Customer
Reviews
Loading...